The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer

详细信息	查看全文 | 推荐本文 |

• 作者：C.S.D. Roxburgh ; ^{campbellroxburgh@doctors.net.uk} ; ^{campbellroxburgh@nhs.net} ; D.C. McMillan
• 关键词：Tumour inflammatory infiltrate ; Immune cells ; In situ response ; Colorectal cancer ; Recurrence and survival
• 刊名：Cancer Treatment Reviews
• 出版年：2012
• 期刊代码：44_03057372
• 类别：med
• 出版时间：August, 2012
• 卷：38
• 期：5
• 页码：451-466
• 文件大小：273 K

摘要

Colorectal cancer progression and survival is dependent on complex interactions between the tumour and the host. The pronounced local inflammatory response in and around the tumour is thought to represent the in situ host anti-tumour immune response. Since early reports, 40 years ago, there has been a continuing interest in establishing the cellular composition of immune cell infiltrates and their relationship with survival in colorectal cancer. In this review, we comprehensively examine the evidence for the local inflammatory cell reaction/in situ immune response in predicting outcome in primary operable colorectal cancer and make recommendations as to how such information may be incorporated into routine clinical assessment.

Generally, an increasing number/density of immune cells in and around the tumour is associated with improved outcome in over 100 studies. Whilst the prognostic value of a generalized lymphocytic infiltrate or non-specific peritumoural inflammatory response is strongly related to survival based on 40 different studies, it is also apparent that most individual immune cell types relate to recurrence and cancer specific survival. The evidence is particularly robust for tumour infiltrating T lymphocytes and their subsets (CD3+, CD8+, CD45RO+, FOXP3+) in addition to tumour associated macrophages, dendritic cells and neutrophils. Taken together, the evidence suggests both adaptive and innate anti-tumour immune responses play key roles in determining cancer progression.

In order to establish routine clinical utility there is a need to rationalise this prognostic information, published over a 40 years period, into a standardized assessment of tumour inflammatory cell infiltrate. Such standardization may also guide development of novel therapeutic interventions.